EQS-News: MorphoSys and Incyte Announce Five-Year Results of

16.04.2023 - EQS-News: MorphoSys AG / Key word(s): Miscellaneous MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi (tafasitamab-cxix) 16.04.2023 / ...

Related Keywords

Canada , Berlin , Germany , Boston , Massachusetts , United States , Orlando , Florida , Hamburg , Planegg , Bayern , Frankfurt , Brandenburg , Hanover , Niedersachsen , University Hospital , Munich , Delaware , American , Johannes Duell , Tim Demuth , Steven Stein , Morphosys Us Inc , Xencor Inc , News Service , Practice Research Clinical Haematology , American Association For Cancer Research Annual Meeting , Twitter , Distribution Services , Tradegate Exchange , Nasdaq , American Association For Cancer Research , Linkedin , Exchange Commission , Drug Administration , Incyte Announce Five Year Results , Showed Prolonged , Durable Responses , American Association , Cancer Research Annual Meeting , Annual Meeting , Medical Clinic , Chief Research , Development Officer , Chief Medical Officer , Diffuse Largeb Cell Lymphoma , Antibody Dependent Cell Mediated Cytotoxicity , Antibody Dependent Cellular Phagocytosis , Medication Guide , Prescribing Information , Patient Information , Important Safety , Morphosy Annual Report , Practice Research , Corporate News , Regulatory Announcements , Prime Standard , Regulated Unofficial Market , Morphosys , Qs News ,